Which Biologic Works Best for Crohn's Disease?

Research-informed explainer — last updated April 12, 2026

No single biologic works best for every person with Crohn's disease. The right choice depends on where your disease is, how severe it is, what medications you've tried before, and your personal priorities around injections versus infusions, side effects, and cost. That said, the clinical trials do give real guidance about how these drugs compare — and the research is now specific enough to help you have a meaningful conversation with your gastroenterologist.

This explainer draws on research from four gastroenterologists in the Convene directory. William Sandborn at UC San Diego Health led the SONIC trial, which established combination therapy with infliximab and azathioprine as more effective than either drug alone for moderate-to-severe Crohn's disease. Edward Loftus at Mayo Clinic co-developed the original and updated STRIDE treat-to-target frameworks that define what "remission" actually means in Crohn's management. Ashwin Ananthakrishnan at Massachusetts General Hospital contributed to genome-wide genetics studies revealing why Crohn's disease behaves differently across patients. Dermot McGovern at Cedars-Sinai directed research identifying 71 confirmed genetic susceptibility loci for Crohn's, providing the biological basis for why different people respond to different therapies.

What is the difference between these biologics?

Biologics for Crohn's disease are not a single category — they work through three distinct mechanisms, and that matters for who should take them.

TNF inhibitors (infliximab, adalimumab, certolizumab pegol) block tumor necrosis factor alpha, a protein that drives the inflammatory signaling at the core of Crohn's flares. These drugs have the longest track record and the most head-to-head data. Infliximab is given by IV infusion; adalimumab and certolizumab are self-injected.

Vedolizumab (Entyvio) works differently — it blocks a protein called integrin alpha4beta7, which stops immune cells from migrating from the bloodstream into the gut lining. Because it acts locally in the GI tract rather than systemically, it doesn't suppress your immune system throughout the rest of your body. It's given by IV infusion every 8 weeks after the initial loading doses.

Ustekinumab (Stelara) targets a different pathway — it blocks IL-12 and IL-23, two signaling proteins that activate inflammatory T-cells. It's given as a single IV infusion to start, then as a subcutaneous injection every 8 or 12 weeks. For patients who have failed TNF inhibitors, ustekinumab is often the next option.

At a glance

When TNF inhibitors are used — and what trials showed

TNF inhibitors are still the first-line biologic for most patients with moderate-to-severe Crohn's disease. The evidence base spans two decades.

The landmark SONIC trial, a double-blind randomized controlled study in 508 patients with moderate-to-severe Crohn's disease, compared three arms: azathioprine (an immunosuppressant) alone, infliximab alone, and infliximab plus azathioprine together [1]. The primary endpoint was corticosteroid-free clinical remission at 26 weeks. Combination therapy achieved remission in 56.8% of patients, compared with 44.4% for infliximab alone and 30.0% for azathioprine alone. Mucosal healing — actual healing of the intestinal lining confirmed by endoscopy — was also higher with combination therapy: 43.9% versus 30.1% for infliximab alone.

The combination result matters because it established a treatment standard that's still in use: for biologic-naive patients with moderate-to-severe Crohn's who are starting infliximab, adding an immunosuppressant (azathioprine or methotrexate) can improve outcomes. The tradeoff is increased risk of certain infections and a rare lymphoma risk, which means combination therapy isn't right for everyone — particularly older patients or those with prior skin cancers.

The ACG Clinical Guideline for Crohn's Disease management, which Edward Loftus helped develop, recommends TNF inhibitors as the primary biologic choice for most patients who need one, while acknowledging that the decision requires weighing disease severity, prior medication history, and individual safety profile [7].

Vedolizumab: gut-selective, slower to work

Vedolizumab's gut-selective mechanism makes it appealing for patients who are worried about the systemic immune suppression that comes with TNF inhibitors. It doesn't cross the blood-brain barrier, and it doesn't suppress immunity in the lungs or other organs the way TNF inhibitors can.

The trade-off is that vedolizumab is generally slower to achieve remission — most patients don't see the full benefit until 14 weeks or later, compared to 6 to 10 weeks for infliximab. Trials showed it is effective for both Crohn's disease and ulcerative colitis induction and maintenance, with remission rates around 14-15% at 6 weeks (versus 6-7% placebo) improving substantially at 52-week maintenance [2]. It's frequently used for patients who have already tried and lost response to a TNF inhibitor, or for patients with infections, demyelinating disease, or other contraindications to TNF blockade.

Ustekinumab: the option after TNF failure

For patients who have tried a TNF inhibitor and either didn't respond or lost response over time, ustekinumab has become the most widely used next step. Its dual blockade of IL-12 and IL-23 addresses a different inflammatory axis. In pivotal trials (the UNIFI program for ulcerative colitis and the IM-UNIFI program for Crohn's), ustekinumab achieved remission rates of about 15-21% after induction and 38-44% at one year in patients who had previously failed TNF inhibitor therapy.

The safety profile is generally favorable — no increased tuberculosis risk (unlike TNF inhibitors), and the injection burden is modest after the initial IV loading dose.

The treat-to-target approach: why remission isn't just about symptoms

One of the most important shifts in how doctors manage Crohn's disease is the move toward "treat-to-target" — a strategy where the goal isn't just making you feel better, but achieving objective evidence that inflammation is controlled.

The STRIDE framework, developed through an international IBD expert consensus process with input from Edward Loftus and William Sandborn, defines those targets [3, 6]. The original STRIDE guidelines (2015) established that symptom control alone isn't enough — the real targets are normalization of inflammatory biomarkers (like CRP and fecal calprotectin) and endoscopic remission (no visible ulcers on colonoscopy). The 2021 STRIDE-II update added transmural healing — full-thickness healing of the bowel wall confirmed by MRI — as an additional long-term goal [3].

This matters for you as a patient because it changes how you should think about whether your treatment is working. If you feel better but your colonoscopy still shows active inflammation, current guidelines suggest your treatment isn't yet at the target and may need to be adjusted or intensified.

What is changing in Crohn's treatment

Two areas are actively changing the options available.

First, biosimilars have dramatically reduced the cost of TNF inhibitor therapy. Generic versions of infliximab (Inflectra, Renflexis, Avsola) and adalimumab (Hadlima, Hyrimoz, and others) are now available in the US and are considered therapeutically equivalent to the branded versions. For many patients, a biosimilar may be the most affordable path to the same biological effect as the original drug.

Second, small molecule drugs — JAK inhibitors like upadacitinib (Rinvoq) — have entered the Crohn's disease space. These are oral pills rather than injections or infusions. They work through a different mechanism than biologics and can act faster, but they carry their own safety considerations including risks of serious infections and a cardiovascular warning for some patients. They're not a replacement for biologics, but they expand options, especially for patients who prefer oral therapy.

The genetic research from Dermot McGovern's group at Cedars-Sinai identified 71 confirmed susceptibility loci for Crohn's disease [9], laying the groundwork for precision medicine approaches — predicting which patients will respond to which biologics based on their genetic makeup. This is still mostly a research tool rather than a clinical one, but it's shaping how future Crohn's trials are designed.

Questions to ask your doctor

• Have I failed any prior biologics, and does that change which drug is appropriate next?
• Should I combine my biologic with an immunosuppressant like azathioprine or methotrexate?
• What are my treat-to-target goals — specifically, when will we do a colonoscopy or imaging to confirm the drug is working?
• Given my disease location (small bowel vs. colon), does vedolizumab make more or less sense than a TNF inhibitor?
• Is there a biosimilar available for the drug you're recommending, and is it covered by my insurance?
• Are there any contraindications to TNF inhibitors for me specifically — prior infections, cancer history, neurological conditions?

The bottom line

TNF inhibitors like infliximab and adalimumab are the most established biologics for Crohn's disease, with the largest evidence base and the longest follow-up. Combination therapy with an immunosuppressant typically outperforms either drug alone for biologic-naive patients. Vedolizumab offers a gut-specific safety profile and is a good option for patients with concerns about systemic immune suppression or prior TNF failure. Ustekinumab is the most widely used option after TNF inhibitor failure, with a favorable safety record and a lower injection burden. No drug is best for everyone — and modern treat-to-target guidelines mean the goal is endoscopic remission, not just feeling better.